Drug intelligence / Profile preview

PLS-2

Development stage: Preclinical
Lead developer: Primetime
Modality: Small Molecules

Overview

PLS-2 is a small molecule antigiardial agent currently in development by Primetime Life Sciences. It is specifically designed for the treatment of Giardiasis, a diarrheal infection caused by the protozoan parasite *Giardia lamblia*. As a next-generation antigiardial candidate, PLS-2 aims to address the limitations of existing therapies, such as drug resistance and adverse effects. The compound is part of a broader pipeline at Primetime Life Sciences focusing on anti-infectives and central nervous system disorders.

Beyond the preview

Go deeper on PLS-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLS-2.

Explore the full profile